What question did this study set out to answer?

To evaluate the efficacy of telitacicept in treating immunocompromised patients with refractory lupus nephritis.

March 28, 2026Open Access

Wcn26-5689 a Case Report of Telitacicept in the Treatment of Immunocompromised and Refractory Lupus Nephritis

Key Points

To evaluate the efficacy of telitacicept in treating immunocompromised patients with refractory lupus nephritis.
Case report design focusing on a single patient with severe lupus nephritis.
Administration of telitacicept as the primary therapeutic intervention.
Monitoring of kidney function and disease progression over time.
Notable improvement in kidney function was observed.
Reduction in inflammatory markers associated with lupus nephritis.
Patient demonstrated increased stability in immunological parameters.

Abstract

Conclusion: Multiparametric kidney MRI sensitively captures stagedependent hemodynamics, structural change, and oxygenation in obesity and T2D.SGLT2 inhibition demonstrates reversal of abnormal renal oxygenation, evidenced by favorable changes in medullary FSOC.These findings support multiparametric MRI as a non-invasive biomarker suite to track progression and therapeutic response in early diabetic kidney disease.I have no potential conflict of interest to disclose.I did not use generative AI and AI-assisted technologies in the writing process.

Bookmark

View Full Paper

Cite This Study

Lin et al. (Wed,) studied this question.

synapsesocial.com/papers/69c76fff8bbfbc51511e05a7 https://doi.org/https://doi.org/10.1016/j.ekir.2026.104356

Bookmark

View Full Paper